alexa Structure-Based Discovery Of A Small Anti-angiogenic Molecule Targeting Neuropilins With In Vivo Anti-tumor Activity | 13314
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

33rd World Congress on Pharmacology

Barcelona, Spain
Share This Page

Structure-Based discovery of a small anti-angiogenic molecule targeting neuropilins with in vivo anti-tumor activity

International Summit on Clinical Pharmacy & Dispensing

Luc Demange

Accepted Abstracts: Clinic Pharmacol Biopharmaceut

DOI: 10.4172/2167-065X.S1.004

Abstract
Angiogenesis, the formation of new vessels from a preexisting vasculature, plays a critical role in several diseases such as cancer. To date, VEGF-A165, a spliced form of VEGFA (vascular endothelial growth factor), has been identified as one of the key proangiogenic factors, and is strongly overexpressed in cancers. VEGF-A165 binds two structurally related receptor tyrosine kinases, VEGFR-1 and VEGFR-2 and neuropilins (NRP-1 and NRP-2). These NRP co-receptors, lacking catalytic activity, form complexes with VEGFR and VEGF-A165 and modulate their effect on the angiogenesis/tumoral signaling pathway. Moreover, NRP over-expression enhances tumor growth and invasion and consequently is associated with a poor prognosis in various cancers. We reasoned that the use of small molecules as antagonists of the protein-protein interaction between VEGF-A165 and NRPs might be an innovative way to identify new anti-tumor drugs. Here we report our use of in silico/in vitro/in vivo screening to discover an original lead. We showed that this molecule antagonizes VEGF-A binding to NRP-1 and NRP-2. In a tubulogenesis assay in HUVECs, we found that our lead compound was involved in the inhibition of tubule formation underlying its involvement in angiogenesis. Furthermore, in vivo experiments on NOG-xenografted mice showed a significant antitumor effect and significantly increased survival.
Biography
Luc Demange completed his Ph.D. in 2001 under the guidance of Dr. C. Dugave on cis-trans isomerization catalyzed by hCyp-18. Then, he moved to Sherbrooke (Canada) and worked with Prof. P. Deslongchamps on steroid synthesis. In 2004-2006, he studied with Prof. J. Martinez ghrelin secretagogs. He joined in 2006 Prof. C. Garbay unit in Paris-Descartes University. His research is currently based on the design and evaluation of protein-protein interaction inhibitors (applied to angiogenesis and AIDS); he also investigated new organic reactions to identify CDKs inhibitors. Luc Demange published more than 25 papers and patents; he was awarded by the French Therapeutic Chemical Society (SCT, 2007).
Top